Tag: Gilead

In June 2025, the FDA approved Yeztugo (lenacapavir), the first and only twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP). For individuals considering this innovative treatment, the pressing question is, "Will insurance cover Yeztugo?".

With a reported first-year list price exceeding $42,000, Sunlenca is a significant investment for heavily treatment-experienced adults with HIV. This sticker shock naturally prompts the question, 'How much is Sunlenca?' for patients, and the answer is complex, depending on a multitude of factors including insurance, financial assistance, and dosing schedules.

Over 1.2 million people in the United States live with HIV, and for many, effective treatment like Biktarvy is crucial. Despite its widespread use, many patients and providers ask, **is there a generic version of Biktarvy**? The answer is complex, involving patent law, regulatory exclusivity, and international drug markets, meaning a generic is not yet available in many countries.

Used by millions of people living with HIV, the medication Biktarvy has a key ingredient called bictegravir, which is often abbreviated as BIC. Understanding what drug is Bic requires looking at this powerful component and its role within the single-tablet regimen used to treat HIV-1 infection.

In June 2025, the U.S. Food and Drug Administration (FDA) approved Yeztugo (lenacapavir) as the first and only twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP). The mechanism of action of Yeztugo involves targeting the viral capsid at multiple points in the HIV-1 life cycle.